



### IG REIMBURSEMENT CALCULATOR



Calculate your current Medicare intravenous immune globulin (IVIG) and subcutaneous immune globulin (SCIG) rates at FFFenterprises.com.

### IG LIVING MAGAZINE

Supporting the IG community through education, communication, and advocacy. Sign up for your FREE subscription at IGLiving.com.



### REIMBURSEMENT QUESTIONS?



Our responsive and dedicated professionals are experienced with every IG product we carry and can answer your questions 24/7 at (800) 843-7477.

## ADDITIONAL PRODUCT INFORMATION

### Liquid Products

The liquid form brands of IVIG and SCIG are variously manufactured in 5%, 10%, 16.5%, and 20% concentrations. Gram-volume relationships are as follows:

10% Liquid IVIG and SCIG Brands*							
1 g	2 g	2.5 g	5 g	10 g	20 g	30 g	40 g
10 mL	20 mL	25 mL	50 mL	100 mL	200 mL	300 mL	400 mL

\*Not all 10% IVIG brands are available in all sizes.

5% Liquid IVIG Brands*					
1 g	2.5 g	5 g	10 g	20 g	25 g
20 mL	50 mL	100 mL	200 mL	400 mL	500 mL

\*Not all 5% IVIG brands are available in all sizes.

20% Liquid SCIG brands*			
1 g	2 g	4 g	8 g
5 mL	10 mL	20 mL	40 mL

\*Not all 20% SCIG brands are available in all sizes.

HYQVIA® (10% Immune Globulin with Recombinant Human Hyaluronidase)					
IG	2.5 g	5 g	10 g	20 g	30 g
	25 mL	50 mL	100 mL	200 mL	300 mL
Hyaluronidase	200 u	400 u	800 u	1600 u	2400 u
	1.25 mL	2.5 mL	5 mL	10 mL	15 mL

16.5% SCIG (CUTAQUIG®)					
1 g	1.65 g	2 g	3.3 g	4 g	8 g
6 mL	10 mL	12 mL	20 mL	24 mL	48 mL



## Service Directory

### Wow! Customer Care Ordering

PLACE AN ORDER - EMERGENCY ORDERS 24/7/365  
 FFFCustomerCare@FFFenterprises.com  
 (800) 843-7477

E-COMMERCE  
 BioSupply.FFFenterprises.com

REGULAR ORDERING HOURS  
 8 AM - 8 PM ET | 7 AM - 7 PM CT  
 6 AM - 6 PM MT | 5 AM - 5 PM PT

SHIPPING  
 FOB Origin - Standard: Overnight  
 FOB Destination - Expedited: Same day

<b>Bio</b> BioSupply™ Online Ordering System BioSupply.fffenterprises.com	<b>MyFluVaccine</b> Respiratory Vaccine Program MyFluVaccine.com	<b>Clinical Trials</b> Providing Management & Support (800) 843-7477	<b>RightNow Inventory™</b> End-to-End Inventory Management (855) 544-2122
<b>Wow! Customer Care™</b> Questions & Orders (800) 843-7477	<b>Comprehensive Product Portfolio</b> Expanding to Meet Your Needs (800) 843-7477	<b>IG</b> IG Living Magazine Immune Globulin Community IGLiving.com	<b>BioSupply Trends Quarterly Magazine</b> Biopharmaceutical Marketplace News BSTQuarterly.com

FFF Enterprises, Inc. is the nation's most trusted specialty drug distributor and diversified healthcare company, supplying healthcare providers and patients with high-quality, counterfeit-free pharmaceuticals. Our partners include global pharmaceutical and biologics manufacturers, prestigious healthcare systems, large and independent retail pharmacies, and leading alternate care sites. Our nationwide commerce is supported by a network of distribution and infusion pharmacy locations utilizing world-class technology and cybersecurity solutions.

FFF Enterprises is dedicated to improving and safeguarding the specialty pharmaceuticals supply chain through Guaranteed Channel Integrity™ – our commitment to purchase product directly from manufacturers and ship it only to licensed healthcare professionals.

From our in-house teams of customer care representatives, advisors and advocates, to our national field team of territory managers, there is a responsive, dedicated expert to care for your product and patient needs 24/7 at (800) 843-7477.



### REFERENCE CHART

## Immune Globulin (Human)



- Anti-Thymocyte Globulin (Rabbit) Products
- Botulism Immune Globulin Products
- Cytomegalovirus Immune Globulin Products
- Hepatitis B Immune Globulin Products
- Rabies Immune Globulin Products
- Rho(D) Immune Globulin Products
- Tetanus Immune Globulin Products
- Varicella Zoster Immune Globulin Products

### PATIENT SAFETY | PRODUCT EFFICACY | FAIR PRICING

EMERGENCY ORDERING 24/7  
 FFFenterprises.com | BioSupply.FFFenterprises.com | (800) 843-7477

### Commitment to Patients

FFF Enterprises continues to set the standard for patient safety, product efficacy, and fair pricing through key partnerships, programs, and services to ensure patients receive high-quality care with responsibly sourced treatments. With over 13,000 consecutive days of supplying providers and patients with counterfeit-free specialty pharmaceuticals, our customers can trust our commitment to providing secure therapies and medical devices.

### Teamwork as Trusted Partners

Since 1988, we have been passionate about our commitment to building strong, trustworthy relationships with our manufacturing partners and patient providers like CVS, Premier, Vizient, and Minnesota Multistate. With our flawless safety track record of counterfeit-free product distribution, we serve approximately 96% of community-based hospitals, more than 74,000 specialty groups, over 25,000 retail pharmacies, and approximately 60% of home infusion providers nationwide.

### Integrity In Responsible Distribution

FFF goes beyond distribution in our commitment to lead with integrity and a patient-centered focus. By constantly seeking innovative solutions to reinforce the safety of the supply chain, maintaining product accessibility, and providing valuable resources – we are making a difference in healthcare. Everything we do affirms our dedication to sustain a reliable, secure pharmaceutical supply chain in the pursuit of our mission of Helping Healthcare Care.™

### Accountability In Leading Industry Innovations

When treating patients, just-in-time isn't good enough, you need RightNow Inventory™

RightNow Inventory™, a subsidiary of FFF Enterprises, Inc., develops and delivers intelligent inventory management and auto-replenishment technology solutions that offer healthcare providers on-site, on-demand management of critical and preventive care medications and medical devices.



Our Lot-Track® service tracks products by lot number and provides recall notifications within four hours directly to those affected.



An end-to-end inventory management program that automates shipments, reduces expiry risk, eliminates carrying costs, and monitors products utilizing the RightNow Inventory™ solution suite.

- Adult Vaccines
- Albumin
- Ancillaries
- Antithrombin
- Antivirals
- Biosimilars
- Biosurgicals
- Brand Pharmaceuticals
- Coagulation
- Controlled Substances
- COVID-19 Vaccines
- Dermatology
- Generic Pharmaceuticals
- Hyperimmune Globulin
- Immune Globulin
- Influenza Vaccines
- Oncology
- Ophthalmology
- Pediatric Vaccines
- RSV Vaccines
- Women's Health



Product Name	ALYGLO™	ASCENIV™	BIVIGAM™	GAMMAGARD® S/D IgA < 1 µg/mL <sup>1</sup>	GAMMAPLEX® 5%	GAMMAPLEX® 10%	Octagam® 5%	Octagam® 10%	PANZYGA™	Privigen®	GAMMAGARD LIQUID™	GAMMAKED™	GAMUNEX™-C	CUTAQUIG™	CUVITRU®	HIZENTRA™	HYQVIA™	XEMBIFY™	GamaSTAN™
Manufacturer/Supplier	GC Biopharma USA	ADMA Biologics	ADMA Biologics	Takeda	Bio Products Laboratory		Octapharma USA		Octapharma USA	CSL Behring	Takeda	Kedrion Biopharma	Grifols	Octapharma USA	Takeda	CSL Behring	Takeda	Grifols	Grifols
Contact Number	(833) 426-6426	(800) 458-4244	(800) 458-4244	(800) 828-2088	(866) 398-0825		(888) 429-4535		(888) 429-4535	(800) 504-5434	(800) 828-2088	(855) 353-7466	(888) 474-3657	(888) 429-4535	(800) 828-2088	(800) 504-5434	(800) 828-2088	(888) 474-3657	(888) 474-3657
Sizes	5 g, 10 g, 20 g	5 g	5 g, 10 g	5 g, 10 g (dilute to 5% or 10%)	5% & 10%: 5 g, 10 g, 20 g		1 g, 2.5 g, 5 g, 10 g, 25 g <sup>3</sup>	2 g, 5 g, 10 g, 20 g, 30 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 30 g	5 g, 10 g, 20 g, 40 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 30 g	5 g, 10 g, 20 g	1 g, 2.5 g, 5 g, 10 g, 20 g, 40 g	1 g (6 mL), 2 g (12 mL), 4 g (24 mL), 8 g (48 mL)	1 g (5 mL), 2 g (10 mL), 4 g (20 mL), 8 g (40 mL), 10 g (50 mL)	1 g (5 mL), 2 g (10 mL), 4 g (20 mL), 10 g (50 mL)	2.5 g (25 mL), 5 g (50 mL), 10 g (100 mL), 20 g (200 mL), 30 g (300 mL) <sup>15</sup>	1 g, 2 g, 4 g, 10 g	2 mL, 10 mL
Storage	2°C to 8°C (36°F to 46°F) for up to 36 months, or RT at 8°C to 25°C (46°F to 77°F) for up to 24 months (without return to RT). Do not freeze.	2°C to 8°C (36°F to 46°F). Within the labeled shelf life, may be stored up to 4 weeks at ≤25°C (77°F). After RT storage, the product must be used or discarded. Do not freeze.	2°C to 8°C (36°F to 46°F). Within the labeled shelf life, may be stored up to 4 weeks at ≤25°C (77°F). After RT storage, the product must be used or discarded. Do not freeze.	Room temperature not to exceed 25°C (77°F). Do not freeze.	2°C to 25°C (36°F to 77°F). Do not freeze. Do not shake.		2°C to 8°C (36°F to 46°F). Within the first 24 months of shelf life, may be stored at ≤25°C (77°F). After storage at ≤25°C (77°F), the product must be used or discarded. Do not freeze.	2°C to 8°C (36°F to 46°F). Within its shelf life, may be stored at ≤25°C (77°F) up to 9 months. After storage at ≤25°C (77°F), use immediately or discard product. Do not freeze.	2°C to 8°C (36°F to 46°F). Within its labeled shelf life, may be stored at ≤25°C (77°F) up to 12 months. After storage at ≤25°C (77°F), use immediately or discard product. Do not freeze.	Room temperature up to 25°C (77°F). Do not freeze.	Refrigerator: 2° to 8°C (36° to 46° F) for up to 36 months. RT: Up to 25°C (77° F) for up to 24 months. <sup>4</sup> Do not freeze.	2-8°C (36-46°F) and may be stored at temperatures not to exceed 25°C (77°F) for up to 6 months anytime during labeled shelf life, after which the product must be discarded. Do not freeze.	2-8°C (36-46°F) and may be stored at temperatures not to exceed 25°C (77°F) for up to 6 months anytime during labeled shelf life, after which the product must be discarded. Do not freeze.	2-8°C (36-46°F) and may be stored at RT up to 25°C (77°F) for up to 9 months (without return to refrigeration) within labeled shelf life. After RT storage, discard if not used. Do not freeze.	2°C to 8°C (36°F to 46°F) or RT (not to exceed 25°C [77°F]). Do not freeze.	Room temperature up to 25°C (77°F) for up to the expiration date printed on the outer carton of the pre-filled syringe or vial label. Do not freeze.	2°C to 8°C (36°F to 46°F). During first 24 months from date of manufacturing, may store up to 25°C (77°F) for 3 months. Do not freeze.	2° to 8°C (36°F to 46°F). XEMBIFY may be stored at temperatures not to exceed 25°C (77°F) for up to 6 months any time prior to the expiration date. Following 25°C (77°F) storage, use the product immediately or discard. Do not freeze. Do not use solutions that have been frozen.	2°C to 8°C (36°F to 46°F). Do not freeze.
Form	Liquid	Liquid	Liquid	Lyophilized	Liquid		Liquid		Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid	Liquid
Reconstitution Fluid	N/A	N/A	N/A	Sterile Water for Injection	N/A		N/A		N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Concentration Options	10%	10%	10%	5% or 10%	5%	10%	5%	10%	10%	10%	10%	10%	10%	16.5%	20%	20%	10% IG with Recombinant Human Hyaluronidase (PH20)	20%	15%-18%
Filtration	Not Required	Not Required	Not required	Product supplied with a transfer device and administration set which includes an integral airway and a 15 micron filter.	If a filtered infusion set is used (not mandatory), the filter size must be 0.2 to 200 microns.		If a filtered infusion set is used (not mandatory), the filter size must be 0.2 to 200 microns.		Not required	Not required	In-line filter optional	Not required	Not required	Not required	Not required	Not required	Not required	Not required	Not required
Indications	PI in adults	PI in adults and adolescents (12 to 17 years of age)	PI	PI (age ≥ 2 years), chronic ITP (adults), B cell chronic lymphocytic leukemia, pediatric Kawasaki disease	PI (age ≥ 2), chronic ITP	PI (age ≥ 2), chronic ITP (adults)	PI	chronic ITP (adults), dermatomyositis (adults)	PI (age ≥ 2 years), CIDP (adults), chronic ITP (adults)	PI, chronic ITP (age ≥ 15 years), CIDP (adults)	IVIG: PI (age ≥ 2 years), MMN (adults), CIDP (adults)    SCIG: PI (age ≥ 2 years)	IVIG: PI (age ≥ 2 years), CIDP (adults), ITP    SCIG: PI (age ≥ 2 years)	IVIG: PI (age ≥ 2 years), CIDP (adults), ITP    SCIG: PI (age ≥ 2 years)	PI age ≥ 2 years	PI (age ≥ 2 years)	PI (age ≥ 2 years), CIDP (adults)	PI (age ≥ 2 years), CIDP (adults)	PI (age ≥ 2 years)	Hepatitis A, measles (rubeola), varicella, rubella <sup>11</sup>
Contraindications	History of anaphylactic or severe systemic reactions to human immune globulin. IgA-deficient patients with antibodies against IgA or a history of hypersensitivity.	History of anaphylactic or severe systemic reaction to administration of human immunoglobulin. IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.	History of anaphylactic or severe systemic reaction to administration of human immunoglobulin. IgA deficient patients with antibodies to IgA and a history of hypersensitivity.	History of anaphylactic or severe systemic reaction to administration of human immunoglobulin. IgA deficiency patients with antibodies to IgA and a history of hypersensitivity. 5% concentration only: Hereditary intolerance to fructose, also in infants and neonates for whom sucrose or fructose tolerance has not been established.	History of acute severe hypersensitivity reactions to human immunoglobulin. IgA-deficient patients with antibodies against IgA and a history of hypersensitivity. Octagam 5%: History of acute hypersensitivity reaction to corn, including corn allergy (Octagam 10%: See Warning/Precaution for patients with corn allergy).	History of anaphylactic or severe systemic reactions to human immune globulin. IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.	History of anaphylactic or severe systemic reaction to human immune globulin. Hyperproliferation (Privigen contains the stabilizer L-proline). IgA-deficient patients with antibodies to IgA and a history of hypersensitivity.	History of anaphylactic or severe systemic reactions to human immunoglobulin. History of hypersensitivity. Anaphylactic or severe systemic reactions to human immunoglobulin.	History of anaphylactic or severe systemic reaction to SC administration of human IG or to any components of CUTAQUIG (e.g. Polysorbate 80). IgA deficient patients with antibodies against IgA and a history of hypersensitivity to human globulin treatment.	History of anaphylactic or severe systemic hypersensitivity reaction to the subcutaneous administration of human immune globulin. IgA deficient patients with antibodies to IgA and a history of hypersensitivity to human immune globulin treatment.	History of anaphylactic or severe systemic reactions to human immune globulin or inactive ingredients of Hizentra, such as polysorbate 80. Hyperproliferation (type I or II); Hizentra contains L-proline as a stabilizer. IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.	History of anaphylactic or severe systemic reactions to the administration of IgG. IgA-deficient patients with antibodies to IgA and a history of hypersensitivity. Known hypersensitivity to hyaluronidase including PH20 of HYQVIA. Known systemic hypersensitivity to human albumin (in the PH20 solution).	History of anaphylactic or severe systemic reactions to human immunoglobulin or inactive ingredients of XEMBIFY such as polysorbate 80. IgA deficient patients with antibodies against IgA and a history of hypersensitivity.	Persons with isolated IgA deficiency. Severe thrombocytopenia or any coagulation disorder or where IM injections are contraindicated. <sup>14</sup>					
Initial Infusion Rate <sup>1</sup>	0.01 mL/kg/min (1 mg/kg/min)	0.5 mg/kg/min (0.005 mL/kg/min) for the first 15 minutes. If tolerated, increase gradually every 15 minutes to a maximum rate of 8 mg/kg/min (0.08 mL/kg/min).	0.5 mg/kg/min (0.005 mL/kg/min) for the first 10 minutes. If tolerated, increase every 20 minutes by 0.8 mg/kg/min (0.008 mL/kg/min) to a maximum rate of 6 mg/kg/min (0.06 mL/kg/min).	The recommended initial 5% solution infusion rate is 0.5 mL/kg/hr. If tolerated, increase gradually to a maximum rate of 4 mL/kg/hr. Patients who tolerate a 5% concentration at 4 mL/kg/hr can be infused with the 10% concentration starting at 0.5 mL/kg/hr and, if tolerated, increased gradually to a maximum rate of 8 mL/kg/hr if no adverse effects occur.	0.5 mg/kg/min (0.01 mL/kg/min) for 30 minutes. If tolerated, increase to 1 mg/kg/min (0.02 mL/kg/min) for 30 minutes, then 2 mg/kg/min (0.04 mL/kg/min) for 30 minutes then to a maximum rate of <3.33 mg/kg/min (0.08 mL/kg/min).	0.5 mg/kg/min (0.01 mL/kg/min) for 30 minutes. If tolerated, increase to 2 mg/kg/min (0.02 mL/kg/min) for 30 minutes, then 4 mg/kg/min (0.04 mL/kg/min) for 30 minutes, then 8 mg/kg/min (0.08 mL/kg/min) for 30 minutes then to a maximum rate of <3.33 mg/kg/min (0.08 mL/kg/min).	1 mg/kg/min (0.01 mL/kg/min) for 30 minutes. If tolerated, increase to 2 mg/kg/min (0.02 mL/kg/min) for 30 minutes to maximum of: PI: 14 mg/kg/min (0.14 mL/kg/min) CIDP: 12 mg/kg/min (0.12 mL/kg/min) ITP: 8 mg/kg/min (0.08 mL/kg/min)	0.5 mg/kg/min (0.005 mL/kg/min). If well tolerated, rate may be increased to a maximum of: PI or CIDP: 8 mg/kg/min (0.08 mL/kg/min) ITP: 4 mg/kg/min (0.04 mL/kg/min)	IVIG: 0.5 mg/kg/min (0.005 mL/kg/min)    SCIG: ≥40 kg body weight: 30 mL/site at 20 mL/hr/site. If <40 kg body weight: 20 mL/site at 15 mL/hr/site.	IVIG: 1 mg/kg/min for PI/ITP and 2 mg/kg/min for CIDP.    SCIG (for PI only): 20 mL/hr per infusion site (adults); see prescribing information for children.	IVIG: 1 mg/kg/min for PI/ITP and 2 mg/kg/min for CIDP.    SCIG (for PI only): 20 mL/hr per infusion site (adults); see prescribing information for children.	IVIG: 1 mg/kg/min for PI/ITP and 2 mg/kg/min for CIDP.    SCIG (for PI only): 20 mL/hr per infusion site (adults); see prescribing information for children.	For subcutaneous use only. Refer to full prescribing information (Section 2.3 Administration) for initial administration rate instructions.	For subcutaneous use only. Refer to full prescribing information (Section 2.3 Administration) for initial infusion rate instructions.	For subcutaneous infusion only. Do not inject into a blood vessel (vein or artery). For first infusion, do not exceed maximum volume of 15 mL per infusion site (PI) or 20 mL per infusion site (CIDP).	For subcutaneous use only. Administer PH20 at an initial rate per site of approximately 1 to 2 mL per minute. Refer to full prescribing information (Section 2.2 Administration) for initial SCIG infusion rate instructions.	For subcutaneous use only. 25 mL/site at ≤25 mL/hr/site.	See full prescribing information for dosing information.	
Other Administration Information <sup>2</sup>	Allow refrigerated product to come to RT before use. Infuse using a separate infusion line. Do not shake. Do not dilute.	Administer at room temperature. If large doses are required, several vials may be pooled using aseptic technique into sterile infusion bags and infused. Do not shake. Do not dilute.	Allow refrigerated product to come to room temperature before use. Do not shake. Do not dilute.	Allow product and diluent to reach RT prior to reconstitution. Begin administration as soon as possible within 2 hours if reconstitution is performed aseptically outside of a sterile laminar air flow hood. <sup>4</sup> Administer reconstituted material at RT. Do not shake.	Administer at room temperature. Infuse using a separate infusion line. An infusion pump may be used to control the rate of administration. For administration of large doses, pool multiple vials using aseptic technique. 5% concentration only: Begin infusion within 2 hours after pooling. Do not shake.	Administer at room temperature. Do not shake. Vials may be pooled using aseptic technique (begin infusion within 8 hours of pooling.) Contains no preservative; use promptly once vial is entered.	Do not mix with other products. Allow product to come to room temperature before use. Do not microwave. Do not shake.	If dilution is required, may be diluted with D5W. Contents of vials may be pooled under aseptic conditions into sterile infusion bags. Use within 8 hours after pooling. Warm to room temperature prior to infusion. Do not shake.	If dilution is required, may be diluted with D5W. Contents of vials may be pooled under aseptic conditions into sterile infusion bags. Use within 8 hours after pooling. Warm to room temperature prior to infusion. Do not shake.	Administer using an infusion pump and compatible syringe(s). Do not dilute CUTAQUIG. Do not shake.	Allow vials to reach room temperature. Do not return CUVITRU to the refrigerator if taken out to room temperature. Do not shake.	Discard all used administration supplies and any unused product immediately after each infusion. Do not shake. <sup>7</sup>	Allow refrigerated product to come to room temperature before use. Use infusion pump capable of infusing at rates up to 300 mL/hr/site. Use a 24 gauge SC needle set labeled for high flow rates. Consider using longer needles (14 or 12 mm rather than 9 mm) and/or >1 infusion site. Do not shake.	Use XEMBIFY within 2 hours of withdrawal from vial to avoid the potential formation of particles caused by siliconized syringes. Do not dilute.	Do not administer subcutaneously or intravenously due to potential for serious reactions. Administer intramuscularly, preferably in the anterolateral aspects of the upper thigh and the deltoid muscle of the upper arm. The gluteal region should not be used routinely.				
Compatibility Issues <sup>3</sup>	Do not mix with other IVIG products or other intravenous medications.	Do not mix with other IVIG products or other intravenous medications.	Do not mix with other IVIG products or other intravenous medications.	Administer separately from other drugs/medications. Do not mix the product with human IVIG products from other manufacturers.	Do not mix with other IV medications (including normal saline) or other IVIG products.	Administer separately from other drugs or medications. The infusion line may be flushed before or after Octagam administration with either normal saline or D5W.	Do not administer PANZYGA simultaneously with another intravenous preparation in the same infusion set, including immune globulin products from another manufacturer.	Do not mix with other IVIG products or other intravenous medications. May be diluted with Dextrose Injection, USP (D5W). Infusion line can be flushed with D5W or 0.9% Sodium Chloride for Injection, USP.	If dilution is desired, D5W may be used as a diluent. Do not use normal saline as a diluent (the infusion line may be flushed with normal saline).	Infuse product by separate line without mixing with other IV fluids or medications. Do not dilute with saline.	Infuse product by separate line without mixing with other IV fluids or medications. Do not dilute with saline.	Do not mix with other products.	Do not mix with other products.	Do not mix Hizentra with other products.	Do not mix the PH20 and 10% immune globulin into the same container prior to administration. Do not mix or administer components of HYQVIA with other products. Flush the infusion line with normal saline or D5W if required.	Do not mix XEMBIFY solution with other medication.	N/A		
IgA Content	≤ 100 µg/mL	≤ 200 µg/mL	≤ 200 µg/mL	<1 µg/mL (5% concentration), <2 µg/mL (10% concentration)	<10 µg/mL	<20 µg/mL	Not more than 200 µg/mL	Average of 106 µg/mL	Average 100 µg/mL	≤ 25 µg/mL	Average 37 µg/mL	Average 46 µg/mL	Average 46 µg/mL	Average 206 µg/mL (0.206 mg/mL)	Average 80 mcg/mL	≤ 50 mcg/mL	Average 37 µg/mL	Average 68 + 19 µg/mL	Not identified in prescribing information.
Stabilizers	Glycine	Glycine, polysorbate 80	Glycine, polysorbate 80	Glycine, glucose, polysorbate 80	D-sorbitol, glycine, polysorbate 80	Glycine, polysorbate 80	Maltose 100 mg/mL <sup>8</sup>	Maltose 90 mg/mL <sup>8</sup>	Glycine	L-proline	Glycine	Glycine	Glycine	Maltose 79 mg/mL <sup>9</sup>	Glycine	L-proline, polysorbate 80	Glycine	Glycine, polysorbate 80	None
Osmolality/Osmolarity	298 mOsmol/kg	≤ 510 mOsmol/kg [Note: Data on file from the manufacturer]	≤ 510 mOsmol/kg [Note: Data on file from the manufacturer]	5% concentration: 636 mOsm/L 10% concentration: 1250 mOsm/L	Not less than 240 mOsm/kg (typically 420 to 500 mOsm/kg)	Not less than 240 mOsm/kg (typically 280 mOsm/kg)	310-380 mOsmol/kg	240-310 mOsmol/kg	320 mOsmol/kg (range 240 to 440 mOsmol/kg)	240-300 mOsmol/kg	258 mOsmol/kg	258 mOsmol/kg	310-380 mOsmol/kg	280 to 292 mOsmol/kg	380 mOsm/kg	240 to 300 mOsmol/kg	280 to 404 mOsmol/kg	N/A	

**GENERAL INFORMATION**

Do not mix immune globulin intravenous (human) products of differing formulations or brands. Do not use reconstituted products if particulate matter or discoloration is seen. Antibodies may interfere with response to live viral vaccines.

The information presented in this guide is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this guide should not be used by clinicians without full evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

KEY	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG	IVIG
CLL	chronic lymphocytic leukemia	IVIG	intravenous immune globulin	PH20	recombinant human hyaluronidase														
CIDP	chronic inflammatory demyelinating polyneuropathy	mL	milliliter	PI	primary immunodeficiency disorders														
IgA	immunoglobulin A	MMN	multifocal motor neuropathy	RT	room temperature														
IMIG	immune globulin intramuscular	mOsm/kg	milliosmoles per kilogram	SCIG	subcutaneous immune globulin														
ITP	immune thrombocytopenic purpura	mOsm/L	milliosmoles per liter	µg	micrograms														

**NOTES**

<sup>1</sup> Additional instructions or special recommendations (e.g., administration to patients at increased risk of acute renal failure) may appear in full prescribing information; always refer to full prescribing information before initiating treatment with any of these products.

<sup>2</sup> Includes selected highlights only; for complete administration instructions, refer to full prescribing information.

<sup>3</sup> Call for availability.

<sup>4</sup> Total storage time depends on timing of transfer to room temperature; see full prescribing information.

<sup>5</sup> Manufacturer of GAMMAGARD S/D with IgA ≤ 2 µg/mL was discontinued after December 2012; manufacturer of GAMMAGARD S/D with IgA < 1 µg/mL will continue. See full prescribing information for contraindications to GAMMAGARD S/D with IgA ≤ 2 µg/mL.

<sup>6</sup> Administer within 24 hours if reconstitution is performed aseptically inside of a sterile laminar flow hood and stored in the original glass container or pooled into ViaFlex bags under constant refrigeration (2°C to 8°C). Record the date and time of reconstitution/pooling. Discard partially used vials.

<sup>7</sup> Product available upon manufacturer approval.

<sup>8</sup> Maltose can be misinterpreted as glucose (resulting in falsely elevated glucose readings) by certain types of blood glucose testing systems. See manufacturer's warning.

<sup>9</sup> Doses may be divided and infused into several sites (refer to full prescribing information for maximum number of sites to use at the same time). Injection sites in the same session should be at least two inches apart. Change injection site with each weekly administration.

<sup>10</sup> Packaged with 1.25 mL, 2.5 mL, 5.0 mL, 10.0 mL and 15.0 mL of recombinant human hyaluronidase (PH20), respectively.

<sup>11</sup> Should not be used for prophylaxis of viral hepatitis type B. Not indicated for routine prophylaxis or treatment of rubella, poliomyelitis, mumps or varicella. Not indicated for allergy or asthma in patients who have normal levels of immunoglobulin. Refer to full prescribing information.

<sup>12</sup> Should be given with caution to patients with a history of prior systemic allergic reactions following administration of human immunoglobulin preparations.